Cotadutide
Sources
registry, as of 2023-11-07Stale
https://clinicaltrials.gov/study/NCT05437848
Chinese Multiple Dose Escalation (MDE) High Dose Study. Overall status COMPLETED. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 16. Conditions Diabetes. A Phase 1 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Cotadutide in Overweight/Obese Subjects with Chinese ancestry with Type 2 Diabetes Mellitus
ClinicalTrials.gov NCT05437848 protocol and results modules
registry, as of 2020-07-31Stale
https://clinicaltrials.gov/study/NCT04208620
Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus. Overall status COMPLETED. Phases PHASE1. Lead sponsor AstraZeneca. Enrollment 16. Conditions Type 2 Diabetes. This is a Phase 1 study designed to assess the safety and tolerability of MEDI0382 (Cotadutide) in Japanese T2DM patients.
ClinicalTrials.gov NCT04208620 protocol and results modules
publication, as of 2021-11-11Stale
https://pubmed.ncbi.nlm.nih.gov/34016612/
Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study. Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. The effects of cotadutide on hepatic and metabolic parameters were e
PMID 34016612